Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AA, abatement, Academy, AF, America, analogize, analogy, anniversary, ANTHEM, arrangement, Asia, book, budget, burden, carcinogenicity, Center, classification, Conversion, copy, Cosentyx, customer, deucravacitinib, developmental, director, disaggregated, discrete, distinct, driven, earliest, England, entirety, entity, evenly, exhibit, expended, FF, foot, highlighted, incremental, input, JNJ, joint, jointly, Journal, lease, leased, literature, LP, Medicine, memetic, met, mg, monoclonal, North, numerator, objective, occupied, OLE, owed, peak, pressure, purport, qualitative, ready, reconciliation, reconciling, relationship, rentable, satisfied, satisfy, satisfying, similarly, Sotyktu, South, space, square, standalone, statement, statutory, Stelara, subcutaneously, sublicensable, Subtopic, suppurativa, susceptible, symptom, Takeda, Taltz, tenant, Territory, threshold, THRIVE, thromboembolic, transition, treated, Tremfya, twelve, uncontrolled, USA, vitro, weather, weekly, withholding
Removed:
ASC, average, back, began, billed, brochure, burn, cancer, CD, collection, component, comprehensive, Crohn, dedicate, default, defaulted, devote, Distinguishing, dollar, enforceable, ensure, equilibrium, exclude, expanded, expiry, GI, hormone, IBD, improving, individual, informed, Innovation, instance, institution, Interleukin, involving, issuable, issuer, JJDC, Johnson, lifted, mechanism, nominated, nomination, pathway, Pennsylvania, pharmacodynamic, pharmacokinetic, profitability, prompted, protecting, PTO, recommended, red, reducing, reflected, regional, regulating, removal, resolution, resumed, revert, scrutinized, signal, solubility, sooner, specifically, stopping, suspected, thrombotic, translation, uninsured, unique, unit, utilize, weighted, wrong
Financial report summary
?Competition
Pfizer • AMGEN • Celgene • Biogen • Astrazeneca • Roche • La Jolla Pharmaceutical • Shire • Arena Pharmaceuticals • NovartisManagement Discussion
- *Percentage not meaningful.
- License and collaboration revenue increased from $0 for the three months ended March 31, 2023 to $255.0 million for the three months ended March 31, 2024. Revenue for the three months ended March 31, 2024 included $254.1 million of the $300.0 million transaction price for the Takeda Collaboration Agreement allocated to the delivery of the rusfertide license to Takeda upon effectiveness of the agreement in March 2024, and $0.9 million allocated to development services provided by us during the period based on the cost-based input method. For the three months ended March 31, 2023, we did not recognize any license and collaboration revenue.
- Research and development expenses increased $6.3 million, or 23%, from $27.4 million for the three months ended March 31, 2023 to $33.7 million for the three months ended March 31, 2024. The increase was primarily due to (i) an increase of $2.9 million in rusfertide clinical and contract manufacturing expenses primarily for the ongoing Phase 3 VERIFY clinical trial and (ii) an increase of $4.3 million in pre-clinical and drug discovery research program expense, partially offset by (iii) a decrease of $0.9 million in expenses for the PN-943 program where further development work was de-prioritized to optimize and focus resources toward the rusfertide program in PV. We